|Bid||6.60 x 1100|
|Ask||6.67 x 800|
|Day's Range||6.50 - 7.04|
|52 Week Range||4.10 - 15.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
Its ex-chief executive officer, John Kapoor, and several former top executives have been charged with conspiracy to illegally distribute Subsys, a mouth-spray form of fentanyl that is approved by the Food and Drug Administration to treat cancer-related pain. Mr. Kapoor has denied wrongdoing and pleaded not guilty. Shares of Insys fell 6% on Tuesday.
Insys Therapeutics Inc said on Tuesday that it believed a previously estimated $150 million would be sufficient to cover expenses from an ongoing litigation related to the company's sales practises. The news comes a day after the U.S. Department of Justice joined a whistleblower lawsuit alleging Insys paid kickbacks to doctors. The company continues to have an ongoing dialogue with the DOJ regarding this investigation, Insys said on Tuesday.
In December 2013, INSYS received a subpoena from the Office of Inspector General (OIG) of the Department of Health and Human Services (HHS), which notified the company of the commencement of an investigation by the DOJ’s Civil Division into the company’s sales and commercial practices and resulted in the company’s corresponding public disclosure. As is often the case, this four-and-a-half-year investigation has been conducted in concert with certain whistleblower litigation that was filed under seal prior to and during the course of the DOJ’s investigation.
The U.S. Department of Justice has joined whistleblower litigation accusing Insys Therapeutics Inc of trying to generate more profit by paying kickbacks to doctors to prescribe powerful opioid medications. It adds firepower to the civil litigation as Insys tries to resolve a federal probe into its marketing of Subsys, a spray form of fentanyl. Six U.S. states - California, Colorado, Indiana, New York, North Carolina and Virginia - also joined whistleblower litigation against Insys, according to the filing in U.S. District Court in Los Angeles.
The U.S. Department of Justice has joined lawsuits accusing Insys Therapeutics Inc of paying kickbacks to doctors to prescribe a powerful opioid medication, in an effort to generate more profit. According to a filing made public on Monday in Los Angeles federal court, the department and six U.S. states intervened in whistleblower litigation against Insys, which has said it had been trying to negotiate a settlement of a federal probe into its marketing of fentanyl-based Subsys. The litigation followed a wave of related criminal cases against medical practitioners and former executives and sales representatives employed by Chandler, Arizona-based Insys, including its billionaire founder John Kapoor.
Shares of the small-cap biotech climbed following news that the company would proceed with inhalation-based dronabinol delivery tests.
The Chandler, Arizona-based company said it had a loss of 28 cents per share. Losses, adjusted for non-recurring costs and stock option expense, came to 19 cents per share. The results matched Wall Street ...
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that it has agreed to an exclusive license partnership with Lunatus for commercialization of SUBSYS® (fentanyl sublingual spray) in the Middle East. Based in Dubai with satellite offices across the Gulf Cooperation Council, Lunatus will be the exclusive licensee for SUBSYS® in Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and the United Arab Emirates. “Partnering with Lunatus will make SUBSYS® available to adult cancer patients in the licensed territory who are suffering episodes of breakthrough cancer pain despite receiving around-the-clock opioid therapy,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics.
Cannabinoid and spray-technology focused pipeline continues to advance, while efforts to stabilize SUBSYS ® revenue continue. PHOENIX, May 08, 2018-- INSYS Therapeutics, Inc., a leader in the development, ...
California joined the list of states to legalize recreational marijuana use at the start of 2018, and the markets are showing some enthusiasm for stocks related to the controversial plant. Attorney General Jeff Sessions is set to rescind an Obama-era rule of federal non-interference in state marijuana law enforcement. Currently, nine states and the District of Columbia have legalized recreational marijuana, while the substance is legal for medical purposes in 29 states. The rush to get in on the marijuana craze has created hundreds of startups, but the odds are that many of these will fail.
NEW YORK, May 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SecureWorks ...
Stock Monitor: Innoviva Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 01, 2018 / Active-Investors.com has just released a free research report on INSYS Therapeutics, Inc. (NASDAQ: INSY ) ("INSYS"). ...
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently initiated a Phase 2 clinical trial of its cannabidiol (CBD) oral solution for evaluation of safety and efficacy in pediatric patients with Prader-Willi syndrome, a rare genetic disease characterized by insatiable appetite in children that often leads to obesity, type 2 diabetes and premature death. Prader-Willi syndrome is the most common genetic cause of obesity that has been identified, affecting upwards of 400,000 people worldwide, according to epidemiological research.
NSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced a collaboration with the University of California (UC) San Diego School of Medicine’s Center for Medicinal Cannabis Research (CMCR) to study cannabidiol (CBD) as a potential treatment for severe symptoms of autism in pediatric patients. INSYS has agreed to provide its pharmaceutical-grade CBD oral solution—already under clinical evaluation in company-sponsored trials for treatment of refractory pediatric epilepsies—for this CMCR study, which is scheduled to start in 2019.
PHOENIX, April 25, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release ...
A former Insys Therapeutics Inc sales representative was sentenced on Monday to six months of home confinement after admitting that she participated in a scheme to pay kickbacks to two Alabama doctors to prescribe a fentanyl-based medication. Natalie Perhacs, 32, was sentenced by U.S. District Judge Callie Granade in Mobile, Alabama, after pleading guilty to conspiring to pay kickbacks to the doctors to prescribe Insys' product Subsys, according to court records.
PHOENIX, April 18, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced plans to advance ...
GW Pharmaceuticals, Insys Therapeutics and Zynerba Pharmaceuticals are using cannabis-based therapies to treat a myriad of disorders, including seizures.
These two biotechs are big losers so far this year. But which has the better shot at being a winner over the long run?
A handful of threats lobbed at opioid-based drugmakers pressured shares of the pain relief specialist following a dismal earnings report.